新型降血糖药物钠-葡萄糖共转运蛋白2抑制剂的不良反应及其预防

Adverse reactions and prevention of a novel hypoglycemic drugs sodium-glucose cotransporter 2 inhibitors

钠-葡萄糖共转运蛋白2(sodium-glucose cotransporter 2,SGLT2)抑制剂是一类新型非胰岛素依赖性降血糖药物,其主要通过抑制近端肾小管对葡萄糖的重吸收,促进葡萄糖从尿液排泄,从而产生降低患者血糖水平的作用。SGLT2抑制剂不仅能改善2型糖尿病患者的高血糖状态,且还具有减轻体质量,降低血压,以及减少心血管事件发生和保护肾脏的效果。当然,SGLT2抑制剂也存在一些不良反应。本文就SGLT2抑制剂的不良反应及其预防作一概要介绍。

Sodium-glucose cotransporter 2(SGLT2)inhibitors is a novel non-insulin-dependent hypoglycemic drugs that can reduce blood glucose in patients by inhibiting glucose reabsorption in proximal renal tubules and promoting glucose excretion from urine.SGLT2 inhibitors can not only improve the hyperglycemia state of patients with type 2 diabetes,but also have the effects of reducing body mass,lowering blood pressure,reducing cardiovascular events and protecting the kidneys.However,there are some adverse reactions in clinical application.This article summarizes the adverse reactions of SGLT2 inhibitors and their prevention.